Transpharmation has considerable understanding in preclinical cognition research gained through decades of experience running disease area portfolios for Alzheimer’s disease, Parkinson’s disease and Schizophrenia within GlaxoSmithKline. Importantly, our highly skilled technical staff appreciate the subtleties involved in evaluating rodent cognitive processes, ensuring all our assays are highly robust and reproducible.
We focus on delivering carefully selected cognition models which are disease-relevant thereby offering the option to evaluate NCEs against pharmacologically induced cognition impairments, (e.g scopolamine) or natural impairments, (age, test parametric manipulation) across multiple disease areas.
Examples of models we offer:
- •Novel object recognition:
- temporal deficit
- pharmacological deficit, (scopolamine, sub-chronic PCP)
- •Delayed-non-match to position
- •Reversal learning
- •Attentional set shifting